{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:09:03Z","timestamp":1785802143664,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.amjcard.2024.04.032","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T07:51:21Z","timestamp":1714463481000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Cardioprotective Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Cancer Treated With Anthracyclines: An Observational Study"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-1692","authenticated-orcid":false,"given":"Ayman R.","family":"Fath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Aglan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Aglan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Chilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatole","family":"Trakhtenbroit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odaye A.","family":"Al-Shammary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oduro","family":"Oppong-Nkrumah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan F.","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince","family":"Otchere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2024.04.032_bib0001","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s10741-020-09968-2","article-title":"Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment","volume":"26","author":"Saleh","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2024.04.032_bib0003","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.2459\/JCM.0000000000000381","article-title":"A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology","volume":"17","author":"Spallarossa","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0004","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose Co-Transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0005","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC Cardiooncol"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0006","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0007","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0008","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0009","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0010","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/10600280231154021","article-title":"Sodium-glucose cotransporter 2 inhibitors among heart failure with mildly reduced and preserved ejection fraction","volume":"57","author":"Cheng","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0011","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1093\/eurheartj\/ehac541","article-title":"SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?","volume":"43","author":"Volpe","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.amjcard.2022.10.054","article-title":"Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy","volume":"188","author":"Subramanian","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100843","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on mortality in hypertrophic cardiomyopathy","volume":"3","author":"Aglan","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0014","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-020-01040-5","article-title":"Empagliflozin prevents doxorubicin-induced myocardial dysfunction","volume":"19","author":"Sabatino","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0016","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0017","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxres\/tfad007","article-title":"Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK\/SIRT-1\/PGC-1alpha-mediated mitochondrial biogenesis","volume":"12","author":"Chen","year":"2023","journal-title":"Toxicol Res (Camb)"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.664181","article-title":"Sodium-glucose CoTransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy","volume":"12","author":"Ren","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0019","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/dom.13745","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials","volume":"21","author":"Dicembrini","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0020","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00018-020-03729-y","article-title":"Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways","volume":"78","author":"Wang","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115686","article-title":"Empagliflozin treatment of cardiotoxicity: a comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications","volume":"168","author":"Vaziri","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0022","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3390\/biomedicines11071867","article-title":"SGLT2 inhibitors as potential anticancer agents","volume":"11","author":"Basak","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.amjcard.2024.04.032_bib0023","unstructured":"ClinicalTrials.gov. Empagliflozin in the prevention of cardiotoxicity in cancer patients undergoing chemotherapy based on anthracyclines. Clinical trial.gov identifier:NCT05271162. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05271162. Accessed on February 10, 2024."}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924003151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924003151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:05:53Z","timestamp":1731045953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914924003151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":23,"alternative-id":["S0002914924003151"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.04.032","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardioprotective Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Cancer Treated With Anthracyclines: An Observational Study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}